Lee Taurman

In a new report focusing on portfolio strategy and business development, my colleagues Cody Powers and Josh Hattem share data around #pharma launches and approvals, what’s driving industry growth, why clinical trials continue to decline and more.  https://lnkd.in/edghcwTS

21

Our latest white paper from #IQVIA Thought Leadership explores the impact of #trialreadouts on #biotech #valuations. A must read for biotech management teams and investors alike.

5

I'm excited to share the next episode of "Life Sciences DNA" podcast series about importance of Data Analytics and AI in behavioral health with Eze Abosi, the Chief Growth Officer of Holmusk. Agilisium Consulting #MentalHealth #AI #DataAnalytics #Pharma #BehavioralHealth

33

Very good article. Appreciating and understanding the health care provider and patient journey/experience is paramount to building meaningful relationships and optimal engagement. A personalized v. one size fits all approach is essential. #hcpengagement #newpharmasalesmodels #changebehaviors

18

Great article describing what is necessary to make in-roads for value-based care. It is not just about one engagement, or one aspect of the costs incurred in treating a disease. This explores how all stakeholders (Payers, Providers and Pharmacists) have to be vested in the concept of value for the patient throughout their journey! #VBC #specialtypharmacy #asembia #revhealth

19

1 Comment

CIOs and IT leaders routinely make a “business case” to secure funding for technology initiatives. Yet, many provider technology projects lose their stakeholder value during execution. Learn how to form powerful partnerships with your C-suite peers in Gartner's complimentary webinar. #Technology #CIO #Leadership #Webinar

5

If you don't know about SMART IRB, you need to. This organization developed a pathway for sites with a local IRB to streamline the process to rely on another institution or central IRB. There are 1200+ institutions that have agreed to use this agreement when relying on an external IRB. This saves days even months in study start up. Univo knows fast, and knows that being part of SMART IRB accelerates connecting patients to research. If you'd like to know more, email info@univo-group.com.

17

I am excited to be partnered with the ADVI Health team! Together, I feel we are exceptionally positioned to enhance biopharma industry strategies, responding effectively to the rapidly evolving market dynamics of value-based care and healthcare quality. #biopharma #pharmaceuticalindustry #marketaccess #commercialstrategy #launchexcellence #healthequity #evidencegeneration #healthpolicy #valuebasedcare #qualitymeasurement #healthcarequality

90

24 Comments

Oracle's Ken Glueck writes last week of his competition: "Everyone in the industry understands that Epic’s CEO Judy Faulkner is the single biggest obstacle to EHR interoperability. She opposes interoperability because it threatens Epic’s franchise. By contrast, Oracle believes outcomes are easier to obtain when providers can collaborate and gain insights across systems, data, and application silos." Which is not incorrect. But markets are about power and control, of getting 'others' to build on and sustain the economic system you started. They're about gravitational pull into your orbit, not technical push into someone else's. And Epic, like UnitedHealth Group and Express Scripts by Evernorth and Mercer, are 'control points' in the American Way of Healthcare. They are the Big EHR and Big Payer and Big PBM and Big EBC writing the source code to keep their flywheels going. They're the apex predators in a blow-up-your-brain ecology of complexity and fragmentation that's getting worse, not better. But if you understand how to #position leverage, if you're fluent in systems thinking, and if you approach #growth as a function of market innovation told and sold with a unique strategy story, then it becomes simple to see space to displace 'the system' that can't be "fixed". Everyone is vulnerable. Published two years ago on #FreshPaint, the Blue Spoon platform dedicated to breaking the hold and the mold of #groupthink keeping healthcare stuck in low-Earth orbit. cc: Chris Gibson, Bharat Sutariya, Michael Fronstin, Nasim Afsar, MD MBA MHM, Brenna Quinn, Patrick Debusha Sargent, LFACHE, Leroy Harris, Jr., Stephanie Trunzo

5

2 Comments

The pharmaceutical landscape is undergoing a transformative shift, driven by advancements in critical areas such as oncology, biosimilars, biologics, and specialty medications for rare and orphan diseases. Asembia's #AXS24 Summit presents a valuable opportunity to engage in discussions around these developments, particularly promising therapies targeting MASH, Alzheimer's, and advancements in oncology drugs and GLP-1s. These advancements reinforce CoverMyMeds' dedication to developing innovative solutions that support our mission to help people get the medicine they need to live healthier lives. What are you looking forward to at #Asembia24? Share your thoughts in the comments below. https://lnkd.in/eMtSuePa

62

#AI can help us deliver healthcare in a world with too few doctors, according to ZS CEO Pratap Khedkar and Principal Ahmed Albaiti. Find out the shifts the industry will need to make—and why the authors are optimistic about a future of healthcare abundance. https://lnkd.in/euCuqhsB

7

Because the health of our planet matters

3

The Inflation Reduction Act (IRA) presents unprecedented challenges for pharmaceutical leadership. As industry executives navigate this new landscape, five critical capabilities emerge as essential for sustainable success: 1️⃣ Sophisticated Pricing and Contracting Strategies The IRA necessitates a reevaluation of pricing models. Value-based and outcome-based pricing strategies are becoming increasingly relevant. Executives should consider how to align drug costs with demonstrable patient outcomes while maintaining financial viability. 2️⃣ Enhanced Market Access and Account Management   With the consolidation of healthcare systems, robust key account management is paramount. Investing in specialized teams capable of navigating complex organizational structures and decision-making processes will be crucial for maintaining market position. 3️⃣ Advanced Data Analytics and Real-world Evidence   The importance of data-driven decision making cannot be overstated. Developing robust capabilities in real-world data collection and analysis will be essential for demonstrating product value, informing pricing discussions, and securing favorable market access. 4️⃣ Comprehensive Patient Support Programs   As the IRA aims to cap out-of-pocket expenses for Medicare beneficiaries, well-designed patient support programs become a strategic imperative. These programs can improve adherence, enhance outcomes, and strengthen overall value propositions to payers and providers. 5️⃣ Digital Transformation and Omnichannel Engagement   The shift towards decentralized, patient-centric healthcare delivery necessitates a corresponding evolution in engagement strategies. Implementing effective digital and omnichannel approaches will be critical for maintaining meaningful connections with healthcare professionals and patients alike. In conclusion, the IRA marks a significant inflection point for our industry. Success in this new era will require strategic foresight, operational agility, and a commitment to innovation across these key areas. I welcome your thoughts on how your organizations are adapting to these changes. What additional strategies are you implementing to ensure continued success in this evolving landscape? #InflationReductionAct #PharmaceuticalStrategy #HealthcareInnovation #AdaptiveLeadership

25

11 Comments

The long awaited IQVIA Institute report on The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028 is here! Please share! Key findings: 1) Overall spending growth in the U.S. market for medicines slowed to 2.5% in 2023, reaching $435Bn at net price level, reflecting a sharp decline in COVID-19 vaccines and therapeutics. 2) Spending growth accelerated to 9.9%, when COVID-19 vaccines and therapeutics are excluded, driven by innovation in areas such as oncology, immunology, diabetes, and obesity. 3) Health services utilization including visits, diagnostics, elective procedures and drugs declined 3% from 2022, reflecting a 4-6% reduction across all indicators except for new prescriptions, which rose 3%. 4) The average out-of-pocket cost per retail prescription increased in 2023, driven primarily by higher brand costs for GLP-1 agonists in diabetes and obesity; however, patient out-of-pocket costs remained less than $20 for 90% of prescriptions. As always, thank you for you and your team's research Murray Aitken! #PharmaSpending #DataScience #USMedicines #HealthcareData #transformhealthcare #savelives What are your thoughts? Eliza Silvester Nitin Patel Matthew Smith Matt Doyle Valerie Eng Gopa Radhakrishnan, MPH Gary Minarich Avinob Roy Carmen Sivakumaren, PhD Abir Yamak, Ph.D. Eric E. Bayir, MSc, MBA Patrick Gorman, PhD Indraneel Mukherjee John DeMarrais Kurt Conger Ben Taylor Alexander Colgan Greg Plante Charles Vizzini Eric Louie, MD Edward Winslow, MD MBA

28

As I prepare to join you all tomorrow at the National Pharmaceutical Congress Institute webinar on Pharmacare featuring experts Mihai (Mike) Csaki, Zal Press, Pamela Fralick, and Eileen McMahon, I wanted to share my thoughts. I picked up 3 key pieces of information to put context, perspectives and opinions on this highly-debated reform. 1. Making contraception and diabetes medications free for Canadians The office of Prime Minister issued a communiqué on May 24. Extracts: ·      The medications many Canadians need are often too expensive, leading to fewer visits to pharmacies, less treatment, and more frequent health scares. ·      The cost of contraceptives, and medications for those who are diabetic, is one of the largest barriers to access. ·      We're making sure Canadians get the medication that they need, when they need it. Source: https://rb.gy/q9hdml 2. Improving Coverage and Access to Innovative Medicines for Canadians: Standing Committee of Health study of Bill C-64 On May 22, Innovative Medicines Canada - Médicaments novateurs Canada issued a position statement including context, four recommendations and proposed next steps for a collaborative approach. Extracts: Reco #1: The Government of Canada should build on Canada’s extensive existing coverage rather than replacing it with limited public formularies. The limited available funding should be used to address the unique gaps or limitations in coverage in consultation with each jurisdiction. Reco #2: The Government of Canada should leverage existing efforts to reduce costs currently being undertaken by the pan-Canadian Pharmaceutical Alliance (pCPA) through joint pricing negotiations. Standalone federal initiatives would have limited additional benefit. Source: https://rb.gy/ihldbw 3. Addressing the impact of Bill-64: Healthcare experts weigh in on the pros and cons of the new legislation This week, the National Pharmaceutical Congress Institute issued a white paper including survey results and opinions from industry experts. Extracts: ·      “With the advent of AI and technology, we are living in dynamic times when it comes to healthcare...We have to be supportive of any initiative that wants our best interests, even if it’s not perfect and we struggle to please everybody. There’s no perfect system for everyone. The goal is to aim for the best and try to improve”. ·      The majority (over 50%) of surveyed participants also believed the greatest challenge in implementing Bill C-64 could be the lack of provincial cooperation. Source: https://lnkd.in/gVdiyGUS I look forward to participating in the event and hearing from the panel as we continue to see the shaping of Canadian healthcare changes. My name is Arnaud Lavenue and I'm a senior partner at Toc Toc Communications. I'm passionate about bringing pharmaceutical brands to life to their full potential so that they can help the patients who need them most. Thank you for liking, commenting, or following.

62

4 Comments

Has your company ever grappled with whether to develop a software solution in-house or outsource it? This crucial decision can have lasting effects on a company’s people, processes, IT ecosystems, and financials. 📣📣 I am thrilled to announce that my colleagues Daniel Choi and Michael Murphy will be delivering a thought-provoking digital strategy presentation next week at Informa Connect’s Life Sciences Pricing & Contracting USA conference. Daniel and Mike will delve into key considerations essential for confidently determining the best strategic path forward based on your company’s unique needs. You'll gain insights through real-world scenarios and different stakeholder viewpoints, including those of executives, business stakeholders, and IT support staff. Join us and learn how we can help your company successfully define and execute on its IT strategies! #digitalstrategy #digitaltransformation #revenuemanagement #GP #SaaS #Informa

21

Icertis goes beyond traditional #CLM solutions by integrating purpose-built #AI with the industry's most extensive enterprise contract data lake—featuring over 2 billion metadata and transactional elements. This powerful combination unlocks unprecedented value for enterprises, enhancing contract efficiency, providing deeper insights, and achieving clearer intent realization. Exploring a CLM solution for your enterprise? MGI Research ranked Icertis as the top leader among 35 companies, excelling in product quality, management, channel engagement, and strategic vision. Check out the report.

2